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Abstract: Background: Silent atrial fibrillation (SAF) is common and is associated with poor outcomes.
Aims: to study the risk factors for AF and SAF in the elderly (≥65 years) general population and
to develop a risk stratification model for predicting SAF. Methods: Continuous ECG monitoring
was performed for up to 30 days using a vest-based system in a cohort from NOMED-AF, a cross-
sectional study based on a nationwide population sample. The independent risk factors for AF
and SAF were determined using multiple logistic regression. ROC analysis was applied to validate
the developed risk stratification score. Results: From the total cohort of 3014 subjects, AF was
diagnosed in 680 individuals (mean age, 77.5 ± 7.9; 50.1% men) with AF, and, of these, 41% had SAF.
Independent associations with an increased risk of AF were age, male gender, coronary heart disease,
thyroid diseases, prior ischemic stroke or transient ischemic attack (ICS/TIA), diabetes, heart failure,
chronic kidney disease (CKD), obesity, and NT-proBNP >125 ng/mL. The risk factors for SAF were
age, male gender, ICS/TIA, diabetes, heart failure, CKD, and NT-proBNP >125 ng/mL. We developed
a clinical risk scale (MR-DASH score) that achieved a good level of prediction in the derivation cohort
(AUC 0.726) and the validation cohort (AUC 0.730). Conclusions: SAF is associated with various
clinical risk factors in a population sample of individuals ≥65 years. Stratifying individuals from
the general population according to their risk for SAF may be possible using the MR-DASH score,
facilitating targeted screening programs of individuals with a high risk of SAF.
Keywords: silent atrial fibrillation; risk factors; risk assessment
1. Introduction
Asymptomatic (‘silent’) atrial fibrillation is common and is associated with poor out-
comes. Given the increasing incidence of atrial fibrillation (AF) worldwide, it is important
to determine the risk factors for AF occurrence, which will allow for rapid diagnosis among
patients who are most predisposed to their development.
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The risk factors for AF are well established and include hypertension, heart failure
(HF), physical activity, obesity, chronic coronary syndromes, chronic kidney disease (CKD),
and hyperthyroidism [1–4]. The determination of risk factors is particularly important
in patients with silent atrial fibrillation (SAF), but their identification is a challenge in
everyday clinical practice and, often, such patients are diagnosed for the first time when
they present with an AF-related complication, such as stroke or heart failure; however,
general population-based data for silent AF (SAF) are limited.
In the EORP-AF registry, SAF occurred more frequently in elderly patients with
more comorbidities (e.g., previous myocardial infarction, previous coronary artery bypass
graft, chronic kidney disease, or peripheral vascular disease) and conferred a higher
thromboembolic risk [5]. Indeed, elderly patients with SAF, and those with SAF associated
with CKD or HF, were at a higher risk of death at 1 year compared to symptomatic patients.
The aim of the present ancillary analysis from the NOMED-AF study is to report the
risk factors for symptomatic AF and SAF in the elderly (≥65 years) general population.
Secondly, we aim to develop a risk stratification model for predicting SAF.
2. Materials and Methods
The NOMED-AF study was a cross-sectional study based on a nationwide sample
of adults aged ≥65 years (n = 3014; mean age 77.5 ± 7.9 years; 50.9% male). A complete
description of the study design and methodology has been published elsewhere [6]. The
aim of NOMED-AF was to assess the frequency of symptomatic and silent AF and identify
their risk profiles in a Polish population of adults aged ≥65 years. The target sample size
comprised 3000 individuals, and enrollment was performed between 15 March 2017 and
10 March 2018. All participants were equipped with a continuous electrocardiogram (ECG)
recording vest for up to 30 days.
Briefly, recruitment to the study was based on a random sampling of individuals aged
≥65 years, regardless of their health status. The sampling was stratified by age, gender,
living environment (urban, rural), and regions (16 districts) to reflect a cross-section of the
Polish elderly population. Written informed consent was obtained from all participants.
The NOMED-AF study was approved by the Local Bioethical Committee (26/2015)
and registered at clinicaltrials.gov (accessed on 15 March 2017) (NCT03243474). The study
procedures consisted of: (i) a survey on either social and health status or medication, (ii) an-
thropometric measurements (body mass, height, etc.), (iii) blood pressure measurements,
and (iv) the collection of biological samples (blood and urine) for further investigation
and long-term continuous ECG monitoring in all recruited individuals. All of the above
procedures were performed on site during two study visits by a professionally trained
study nurse.
2.1. ECG Monitoring and Clinical Assessments
All participants were equipped with a continuous electrocardiogram (ECG) recording
vest for up to 30 days. They were encouraged to wear the vest for the maximum possible
time, with short breaks for either hygiene (washing) or other necessary reasons only. The
ECG signal was transmitted to the Integrated Medical Algorithms Platform (Comarch
Healthcare S.A., Krakow, Poland). All episodes automatically classified as AF by the
platform’s software were verified and finally confirmed as AF by cardiologists. According
to the current ESC guidelines [1], only participants with AF episodes lasting longer than
30 s were included in the analysis as AF-positive individuals. Silent AF was defined as
AF that was detected and confirmed by cardiologists in asymptomatic individuals. The
scheme of the long-term ECG monitoring system is shown in Figure 1.




Figure 1. Central illustration: The scheme of the long-term ECG monitoring system used in the NOMED-AF study. 
To determine the possible risk factors, clinical parameters that could have an impact 
on the occurrence of AF and/or SAF were retrieved for risk stratification analysis. The 
recorded data included demography, cardiovascular diseases (including myocardial in-
farction, HF, previous revascularization, hypertension, previous stroke, and thromboem-
bolic disease), metabolic diseases (i.e., diabetes mellitus or thyroid disease), chronic kid-
ney diseases, chronic obstructive pulmonary disease, and relevant biomarkers. 
Hypertension (HA) was diagnosed if the average blood pressure values from two 
measurements during each visit were equal to or higher than 140 mmHg (systolic) and/or 
90 mmHg (diastolic), or if the patient had taken antihypertensive drugs in the previous 2 
weeks because of an earlier diagnosis of hypertension, as per the 2018 ESC/European So-
ciety of Hypertension guidelines for the management of arterial hypertension [7]. Diabe-
tes mellitus (DM) was diagnosed when hemoglobin A1c was ≥6.5%, or if the patient was 
Figure 1. Central illustration: The scheme of the long-term ECG monitoring system used in the NOMED-AF study.
To determine the possible risk factors, clinical parameters that could have an impact
on the occurrence of AF and/or SAF were retrieved for risk stratification analysis. The
recorded data included demography, cardiovascular diseases (including myocardial infarc-
tion, HF, previous revascularization, hypertension, previous stroke, and thromboembolic
disease), metabolic diseases (i.e., diabetes mellitus or thyroid disease), chronic kidney
diseases, chronic obstructive pulmonary disease, and relevant biomarkers.
Hypertension (HA) was diagnosed if the average blood pressure values from two
measurements during each visit were equal to or higher than 140 mmHg (systolic) and/or
90 mmHg (diastolic), or if the patient had taken antihypertensive drugs in the previous
2 weeks because of an earlier diagnosis of hypertension, as per the 2018 ESC/European
Society of Hypertension guidelines for the management of arterial hypertension [7]. Dia-
betes mellitus (DM) was diagnosed when hemoglobin A1c was ≥6.5%, or if the patient
was aware of their diabetes an as taking lucose-lowering agents, in accordance with
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the 2019 American Diabetes Association and 2019 ESC/European Association for the Study
of Diabetes criteria [8,9]. The hemoglobin A1c test was performed using a method certified
by the National Glycohemoglobin Standardization Program, certified and standardized
to the Diabetes Control and Complications Trial assay. CKD was defined as an estimated
glomerular filtration rate <60 mL/min/1.73 m2 or ≥60 mL/min/1.73 m2 with coexisting
albuminuria (albumin-to-creatinine ratio ≥30 mg/g) using the 2009 Chronic Kidney Dis-
ease Epidemiology Collaboration formula [10–12]. Definitions of these medical conditions
are summarized in Supplementary Materials Table S1 (online appendix).
2.2. Statistical Analysis
All statistical analyses were performed using SPSS v19 (IBM Corp., Armonk, NY,
USA). The risk factor analysis was conducted on a sample weighted to the Polish popu-
lation, taking into account the complex sampling scheme. The distributions and the 95%
confidence intervals of the risk factors were obtained for the AF and SAF groups. The
significance was tested by chi2 and t-tests for age. Risk factors associated with AF or SAF
were first identified using univariate, then multivariate logistic regression. Odds ratios
(OR), their significance, and their 95% confidence intervals were obtained.
Based on the recognized risk factors, we constructed a risk prediction scheme for silent
atrial fibrillation (MR-DASH score), focused on including only components that are easily
accessible as part of patients’ daily routines and which do not require additional testing.
Hence, we included all identified factors in our risk scale, omitting high NT-proBNP levels.
To create this risk score, the study population without overt AF was randomly divided in
proportions of 2/3 to 1/3, as derivation and validation cohorts, respectively. The relative
contribution of particular risk factors to total risk and their significance were evaluated on
the basis of 2/3 of the randomly divided population using multivariate logistic regression.
This procedure was repeated five times to confirm the consistency of the model.
The final score was defined as the sum of the rounded ORs associated with risk factors,
which were significant in 4 or 5 draws. For the risk factors that were significant in 3 or less
draws, the score was set to one and added to the final score. Subsequently, the clinical risk
score was validated on the remaining 1/3 of the divided population. The c-statistics (AUC)
and cutoff value for the proposed scale were calculated with the use of receiver operating
characteristic (ROC) analysis to obtain the best balance between sensitivity and specificity.
This procedure was also repeated five times to confirm the consistency of the model. The
cutoff point was established based on the method of minimal distance to the point (0;1).
Finally, the positive (PPV) and negative (NPV) predictive values were calculated separately
for each of the 5 draws. p values < 0.05 were considered statistically significant.
3. Results
In this nationwide population sample, we enrolled 3014 subjects (mean age,
77.5 ± 7.9 years; women, 1479), and long-term ECG monitoring was performed in 2974
(98.7%). The median effective time of monitoring (the time of acquisition of an ECG signal
with a quality sufficient for analysis) was 23 days, 10 h, and 26 min (range: 12 min–37 days,
19 h 4 min).
The overall number of individuals that appeared to have AF (symptomatic or silent)
was 680 (22.6%). Of these, symptomatic atrial fibrillation was present in 401 (13.3%) and
279 (9.3%) had SAF. The detailed demographic and clinical characteristics of the study
population are summarized in Table 1.
J. Clin. Med. 2021, 10, 2321 5 of 11





N % N % N % p(AF− vs. AF) N %
p
(AF− vs. SAF)
Age (years, mean ± SD) 77.5 7.9 76.8 7.9 80.0 7.4 <0.001 80.9 7.4 <0.001
Male gender 1535 50.9% 1122 48.1% 413 60.7% <0.001 191 68.5% <0.001
MI 446 14.8% 321 13.8% 125 18.4% 0.003 45 16.1% 0.294
CHD 666 22.1% 444 19.0% 222 32.6% <0.001 84 30.1% <0.001
Thyroid diseases 418 13.9% 301 12.9% 117 17.2% 0.005 42 15.1% 0.337
Pulmonary diseases 361 12.0% 264 11.3% 97 14.3% 0.040 32 11.5% 0.974
Thromboembolism 241 8.0% 166 7.1% 75 11.0% 0.001 23 8.2% 0.513
LEAD 415 13.8% 286 12.3% 129 19.0% <0.001 51 18.3% 0.005
ICS/TIA 366 12.1% 246 10.5% 120 17.6% <0.001 53 19.0% <0.001
PCI/CABG 368 12.2% 270 11.6% 98 14.4% 0.043 44 15.8% 0.040
DM 881 29.2% 628 26.9% 253 37.2% <0.001 98 35.1% 0.004
Heart failure 673 22.3% 396 17.0% 277 40.7% <0.001 96 34.4% <0.001
HA 2433 80.7% 1856 79.5% 577 84.9% 0.001 223 79.9% 0.821
CKD 1005 33.3% 695 29.8% 310 45.6% <0.001 144 51.6% <0.001
Physical activity 1294 42.9% 1039 44.5% 255 37.5% 0.001 103 36.9% 0.017
BMI ≥ 30 923 30.6% 686 29.4% 237 34.9% 0.005 88 31.5% 0.419
hs CRP > 5 mg/L 565 18.7% 434 18.6% 131 19.3% 0.659 56 20.1% 0.603
NT pro-BNP > 125
pg/mL 2288 75.9% 1690 72.4% 598 87.9% <0.001 247 88.5% <0.001
AF—atrial fibrillation. SAF—silent atrial fibrillation. MI—myocardial infarction CHD—coronary heart disease; LEAD—lower extremity
artery disease. ICS—ischemic cerebral stroke; TIA—transient ischemic attack; DM—diabetes mellitus; HA—arterial hypertension; CKD—
chronic kidney disease; BMI—body mass index.
3.1. Independent Risk Factors for Atrial Fibrillation
In the multivariable analysis, age, male gender, coronary heart disease, thyroid dis-
eases, prior ischemic stroke or transient ischemic attack, diabetes, heart failure chronic
kidney disease, obesity (BMI > 30), and an NT-proBNP level above the reference range
(>125 ng/mL) were independent risk factors for AF (Table 2). Prior revascularization,
either percutaneous or surgical, was associated with a decreased risk of AF but not of SAF.
Age, male gender, prior ICS/TIA, diabetes, heart failure, chronic kidney diseases, and
an NT-proBNP level above the reference range (>125 ng/mL) were risk factors for SAF
(Table 2).
3.2. Predicting Silent Atrial Fibrillation in Subjects Aged over 65 Years
The results of the risk factor analysis for five subsequent draws and the assigned scores
are presented in Table 3. All of the included risk factors were significant in at least one
draw. The allocation of points on the scale was based on the consistency and height of the
statistical significance and the relative risk contribution of the specified factors. We assigned
three points to “age over 75 years” due to its consistently high odds ratios and statistical
significance. Two points were assigned to the following: male sex, heart failure, and a
history of ischemic stroke/transient ischemic attack (ICS/TIA). One point was assigned to
diabetes and chronic kidney disease due to the fact that they had the lowest odds ratios
and borderline significance (Table 3). The randomly allocated 1/3 of the study population
was used for the validation of the proposed scale (MR-DASH; M—male, R—renal failure,
D—diabetes, A—age, S—stroke/TIA, H—heart failure). Regardless of the sample drawn,
the calculated C-statistics based on the receiver operating characteristic (ROC) analysis
ranged between 0.726 and 0.709 or between 0.730 and 0.678 for the derivation and validation
cohorts, respectively. The optimal cutoff point established based on the method of the
minimal distance to the point (0.1) was 4.5. the ROC curves obtained for all draws and
calculated c-statistics are shown in Figure 2.
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Table 2. Multivariate analysis of the main risk factors for the occurrence of atrial fibrillation and
silent atrial fibrillation.
AF Overall SAF
Parameter OR 95% CI p OR 95% CI p
Age (every 5 years) 1.26 1.17–1.35 <0.001 1.36 1.24–1.49 <0.001
Male gender 2.05 1.67–2.51 <0.001 2.58 1.94–3.44 <0.001
MI 0.96 0.70–1.30 0.776 0.68 0.41–1.12 0.131
CHD 1.30 1.01–1.66 0.043 1.10 0.77–1.57 0.592
Thyroid diseases 1.44 1.09–1.90 0.010 1.41 0.98–2.03 0.066
Pulmonary diseases 0.87 0.65–1.17 0.353 0.67 0.43–1.04 0.073
Thromboembolism 1.28 0.91–1.81 0.157 1.41 0.83–2.41 0.204
LEAD 0.96 0.73–1.26 0.761 1.11 0.76–1.62 0.593
ICS/TIA 1.28 1.00–1.64 0.051 1.59 1.16–2.18 0.004
PCI/CABG 0.43 0.30–0.61 <0.001 0.64 0.39–1.06 0.084
DM 1.39 1.12–1.72 0.003 1.48 1.10–1.98 0.009
Heart failure 2.98 2.33–3.80 <0.001 2.06 1.46–2.90 <0.001
HA 1.29 0.97–1.72 0.077 0.85 0.60–1.19 0.344
CKD 1.25 1.00–1.56 0.045 1.39 1.06–1.84 0.019
Physical activity 1.03 0.82–1.29 0.813 1.02 0.78–1.34 0.860
BMI ≥ 30 1.43 1.14–1.78 0.002 1.21 0.92–1.59 0.175
hs CRP >5 mg/L 0.89 0.67–1.19 0.438 0.83 0.59–1.15 0.260
NT pro-BNP > 125 pg/mL 1.95 1.44–2.64 <0.001 2.37 1.493.76 <0.001
AF—atrial fibrillation. SAF—silent atrial fibrillation. MI—myocardial infarction CHD—coronary heart dis-
ease; LEAD—lower extremity artery disease. ICS—ischemic cerebral stroke; TIA—transient ischemic attack;
DM—diabetes mellitus; HA—arterial hypertension; CKD—chronic kidney disease; BMI—body mass index.
Table 3. Rationale for the risk scale for SAF.





OR 2.39 1.78 1.34 2.66 1.70 1.63
95% CI 1.68–3.38 1.24–2.55 0.93–1.92 1.83–3.87 1.07–2.71 1.09–2.43
P 0.020 0.002 0.115 <0.001 0.025 0.016
Sample/Draw
2
OR 1.54 1.39 1.39 3.30 1.57 2.02
95% CI 1.07–2.21 0.95–2.05 0.95–2.04 2.21–4.92 0.96–2.57 1.34–3.05
P <0.001 0.092 0.093 <0.001 0.073 0.001
Sample/Draw
3
OR 2.13 1.31 1.29 3.10 1.94 2.10
95% CI 1.48–3.06 0.89–1.93 0.88–1.89 2.10–4.57 1.22–3.09 1.40–3.15
P <0.001 0.171 0.197 <0.001 0.005 <0.001
Sample/Draw
4
OR 1.99 1.88 1.37 2.34 1.98 1.85
95% CI 1.41–2.81 1.31–2.69 0.96–1.96 1.62–3.38 1.27–3.10 1.26–2.72
P <0.001 0.001 0.086 <0.001 0.003 0.002
Sample/Draw
5
OR 2.50 1.43 1.51 2.83 1.76 1.88
95% CI 1.75–3.59 0.98–2.08 1.04–2.20 1.93–4.15 1.09–2.84 1.25–2.83













Score 2 1 1 3 2 1
Weight of selected risk factors on the basis of five subsequent random splits of study population in derivation (2/3 of study population)
and validation groups (1/3 of study population). ICS/TIA—ischemic cerebral stroke/transient ischemic attack; DM—diabetes mellitus;
CKD—chronic kidney disease.
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4—0.730: 0.676–0.783, 4.5. Sample 5—0.706: 0.52–0.760, 4.5.
The sensitivities, specificities, and positive and negative predictive values of the
MR-DASH scale are presented in Table 4.
Table 4. Sensitivity, specificity, and positive and negative predictive values of designed risk scale, calculated based on five
subsequent random splits of the study population in the derivation (2/3 of the study population) and validation cohorts
(1/3 of the study population).
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4. Discussion
To the best of our knowledge, the NOMED-AF study is the only large-volume investi-
gation that utilizes continuous, long-term, noninvasive ECG monitoring for the detection
of AF. In this analysis from NOMED-AF, our principal findings are as follows: (i) The main
risk factors for SAF were age, male gender, prior ICS/TIA, diabetes, heart failure, CKD,
and NT-proBNP > 125 ng/mL; and (ii) a simple clinical risk scale (MR-DASH score) was
developed, which had a good level of prediction in the derivation cohort (AUC 0.726) and
the validation cohort (AUC 0.730).
Due to the applied methodology of NOMED-AF, the obtained data are representative
of the entire Polish population over 65 years old. In the present work, we sought risk factors
for either overall or silent atrial fibrillation. As mentioned earlier, the method of atrial
fibrillation search utilized in this study was based on long-term ECG monitoring. Thus,
the AF diagnoses in the subjects studied in our analysis followed the diagnostic criteria of
the recently published ESC guidelines [1]. A European Heart Rhythm Association (EHRA)
survey showed that the most common method of SAF identification is 24-h Holter ECG
records, especially in patients who have experienced a cryptogenic stroke [7]. Although
new technologies are emerging to detect arrhythmias, they are not sensitive enough to
confirm the diagnosis of AF and if AF is suspected, verification by performing an ECG is
necessary [13,14]. When comparing 24-h Holter ECG records with 30-day event-triggered
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recorders in patients with cryptogenic stroke, the EMBRACE study showed that patients
undergoing 30-day triggered monitoring showed a 5-fold higher rate of SAF [8]. A higher
prevalence of SAF, between 12.4% and 46%, was even detected using implantable loop
recorders (ILRs) in patients after cryptogenic stroke in observations over 1 year or longer.
These findings emphasize the need for long-term continuous monitoring in the evaluation
of the true prevalence of SAF. In both studies, with the use of ILR, the highest incidence
of newly appeared AF episodes were detected in the first 30 days of monitoring. Hence,
our continuous ECG monitoring method, lasting up to 30 days, seems to provide reliable
data on the overall and silent AF prevalence in the study population. Additionally, the
definitions of some medical conditions (diabetes, hypertension, chronic kidney diseases,
thyroid diseases) introduced in our analysis were based not only on medical history and
prescribed medication, but also on the results of direct diagnostic tests applied to the whole
study population and interpreted according to the current guidelines [9–12,15,16]. Such an
approach significantly strengthens the reliability of the analysis performed.
The risk factor profile of overall (overt and silent) AF was consistent with previous
data [1,3,17–19]. Only hypertension, which is a generally accepted risk factor of atrial
fibrillation, was on the borderline of statistical significance, perhaps reflecting the relatively
high prevalence of hypertension (79.5%) in subjects without AF (Table 1). Contrary to
the overall AF cohort, some factors, such as coronary heart disease (CHD), obesity, and
thyroid diseases, were not significantly predictive of SAF risk; however, thyroid diseases
displayed marginal p-values, which might be due to their reduced power in the SAF group.
Until now, it was believed that ‘general’ (i.e., overall) and silent AF share the same risk
factors [5,20,21]. However, our observations suggest that the risk profiles of overt and
silent AF overlap but are not identical. The differences in the risk factors between overt AF
and SAF relate to CHD, obesity, and thyroid diseases. To classify AF as SAF, two conditions
must be granted: AF must occur, and it must be asymptomatic. It is possible that, in
individuals with obesity, coronary heart diseases, or thyroid diseases, AF symptoms are
more frequent. This can be partially explained by the younger age of individuals with the
aforementioned conditions. Indeed, younger subjects are more symptomatic than older
subjects due to their more efficient atrio-ventricular conduction, leading to a faster heart
rhythm and the feeling of palpitations.
Although some risk scores, such as CHARGE-AF, Framingham, ARIC, and
CHA2DS2VASc, may be useful for risk stratification in patients suspected of having
AF [5,22], no scale for the assessment of SAF risk has yet been developed. However,
our newly developed SAF score is able to select low-risk subjects. Additionally, the results
of our ROC analysis suggest the consistently good predictive value of this schema, with
c-statistics comparable to other published AF prediction schema [15,23–29]. Our proposed
SAF scores allow for the identification of subjects who do not require active or intense
searching for SAF. Thus far, there are no RCT data that might support the hypothesis
that screening for SAF might have potential implications on reducing MACE rates in
the elderly; however, based on the MR-DASH scale, such a study could be performed.
Further validation of this approach to stratification should be performed in everyday
clinical practice.
Strengths and Limitations
This study provides several novel contributions, including the determination of in-
dependent risk factors for SAF and the proposal of a simple score (SAF score) to identify
asymptomatic individuals with a low risk of SAF. Our scale is not intended for application
in high-risk patients (e.g., patients after cryptogenic stroke), which a priori require an active
AF search, but rather to identify asymptomatic patients of low risk who do not require
active and systematic SAF searching. As shown in this study, our scale’s consistently high
negative predictive value makes it a useful tool in such applications.
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5. Conclusions
SAF is associated with various clinical risk factors in a population sample of individu-
als ≥ 65 years. Stratifying individuals from the general population according to their risk
of SAF may be possible using the MR-DASH score, facilitating targeted screening programs
in individuals with a high risk of SAF.
6. Clinical Perspectives
6.1. Competency in Medical Knowledge
The risk factors of AF were identified. However, the specific risks associated with
silent atrial fibrillation in the general population have not been well characterized. The
identification of those risk factors would allow us to better delineate the population at risk
of SAF.
6.2. Competency in Patient Care
The identification of patients with a low risk of silent atrial fibrillation allows us
to concentrate population screening in the moderate- and high-risk population. This
would facilitate the identification of subjects with SAF and accelerate the introduction of
required treatments.
6.3. Translational Outlook
The results of our study should provide the rationale for the organization of systemic
populational screening for SAF.
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